Pre-Clinical efficacy and safety of experimental vaccines based on Non-Replicating vaccinia vectors against yellow fever

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Schäfer, Birgit ^a   Holzer, Georg W ^a   Joachimsthaler, Alexandra ^a   Coulibaly, Sogue ^a   Schwendinger, Michael ^a   Crowe, Brian A ^a   Kreil, Thomas R ^a   Barrett, P Noel ^a   Falkner, Falko G ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; LIVE VACCINE; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; VACCINIA VECTOR; VIRUS VECTOR; YELLOW FEVER VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; GENE INSERTION; IMMUNE RESPONSE; IMMUNOGENICITY; MORTALITY; MOUSE; NONHUMAN; SINGLE DRUG DOSE; VACCINIA VIRUS; VIRUS IMMUNITY; VIRUS RECOMBINANT; VIRUS STRAIN; WILD TYPE; YELLOW FEVER; ANIMAL; BAGG ALBINO MOUSE; CERCOPITHECUS; CHEMISTRY; HELA CELL; HUMAN; IMMUNE SYSTEM; METABOLISM; PLASMID; VERO CELL; VIROLOGY;

MUS; VACCINIA VIRUS; VACCINIA VIRUS ANKARA; YELLOW FEVER VIRUS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CERCOPITHECUS AETHIOPS; HELA CELLS; HUMANS; IMMUNE SYSTEM; MICE; MICE, INBRED BALB C; PLASMIDS; VACCINES, ATTENUATED; VACCINIA VIRUS; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 80052592683     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024505     Document Type: Article

References (71)

1. WHO (2009) Yellow fever. Yellow Fever fact sheet No 100 (http://www.who.int/mediacentre/factsheets/fs100/en/).
2. Lindenbach BD, Thiel HJ, Rice CM, (2007) Flaviviridae: The viruses and their replication. In: Knipe DM, Howley PM, editors. Fields Virology 5th ed Philadelphia, PA Lippincott Williams & Wilkins pp. 1101-1152.
3. Monath TP, (2004) Yellow Fever. In: Plotkin SA, Orenstein WA, editors. "Vaccines" pp. 1095-1176 4th ed.
4. Gubler DJ, Kuno G, Markoff L, (2007) Flaviviruses. In: Knipe DM, Howley PM, editors. Fields Virology 5th ed Philadelphia, PA Lippincott Williams & Wilkins pp. 1153-1252.
5. Monath TP, (2001) Yellow fever: an update. Lancet Infect Dis 1: 11-20.
6. Monath TP, Barrett AD, (2003) Pathogenesis and pathophysiology of yellow fever. Adv Virus Res 60: 343-395.
7. Stokes A, Bauer JH, Hudson NP, (2001) The transmission of yellow fever to Macacus rhesus. 1928. Rev Med Virol 11: 141-148.
8. Theiler M, Smith HH, (1937) The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 65: 787-800.
9. Barrett AD, (1997) Yellow fever vaccines. Biologicals 25: 17-25.
10. Monath TP, (2007) Dengue and yellow fever-challenges for the development and use of vaccines. N Engl J Med 357: 2222-2225.
11. Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, et al. (2008) Adverse event reports following yellow fever vaccination. Vaccine 26: 6077-6082.
12. Doblas A, Domingo C, Bae HG, Bohorquez CL, de OF, et al. (2006) Yellow fever vaccine-associated viscerotropic disease and death in Spain. J Clin Virol 36: 156-158.
13. Martin M, Tsai TF, Cropp B, Chang GJ, Holmes DA, et al. (2001) Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 358: 98-104.
14. Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, et al. (2001) Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 358: 91-97.
15. Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, et al. (2001) Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 358: 121-122.
16. Kengsakul K, Sathirapongsasuti K, Punyagupta S, (2002) Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 85: 131-134.
17. Belsher JL, Gay P, Brinton M, DellaValla J, Ridenour R, et al. (2007) Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 25: 8480-8485.
18. Gerasimon G, Lowry K, (2005) Rare case of fatal yellow fever vaccine-associated viscerotropic disease. South Med J 98: 653-656.
19. Brandriss MW, Schlesinger JJ, Walsh EE, (1990) Immunogenicity of a purified fragment of 17D yellow fever envelope protein. J Infect Dis 161: 1134-1139.
20. Pincus S, Mason PW, Konishi E, Fonseca BA, Shope RE, et al. (1992) Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology 187: 290-297.
21. Putnak JR, Schlesinger JJ, (1990) Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b. J Gen Virol 71 (Pt 8): 1697-1702.
22. Brandriss MW, Schlesinger JJ, Walsh EE, Briselli M, (1986) Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol 67 (Pt 2): 229-234.
23. Monath TP, Lee CK, Julander JG, Brown A, Beasley DW, et al. (2010) Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 28: 3827-3840.
24. Liu T, Chambers TJ, (2001) Yellow fever virus encephalitis: properties of the brain-associated T-cell response during virus clearance in normal and gamma interferon-deficient mice and requirement for CD4+ lymphocytes. J Virol 75: 2107-2118.
25. Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, et al. (2009) The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 183: 7919-7930.
26. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, et al. (2008) Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710-722.
27. van der Most RG, Harrington LE, Giuggio V, Mahar PL, Ahmed R, (2002) Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. Virology 296: 117-124.
28. Co MD, Terajima M, Cruz J, Ennis FA, Rothman AL, (2002) Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology 293: 151-163.
29. Maciel M Jr, Kellathur SN, Chikhlikar P, Dhalia R, Sidney J, et al. (2008) Comprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB/c (H2d) mice model. Virology 378: 105-117.
30. Mayr A, Hochstein-Mintzel V, Stickl H, (1975) Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 3, Nr 1.
31. Brookes RH, Hill PC, Owiafe PK, Ibanga HB, Jeffries DJ, et al. (2008) Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS One 3: e2921.
32. Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, et al. (2006) Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24: 417-425.
33. Bejon P, Ogada E, Mwangi T, Milligan P, Lang T, et al. (2007) Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS One 2: e707.
34. Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, et al. (2009) Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med 7: 2.
35. Drexler I, Staib C, Sutter G, (2004) Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 15: 506-512.
36. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, et al. (1974) [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch Med Wochenschr 99: 2386-2392.
37. Mayr A, Stickl H, Muller HK, Danner K, Singer H, (1978) [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol B 167: 375-390.
38. Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, et al. (2008) Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother 57: 977-986.
39. Wyatt LS, Carroll MW, Czerny CP, Merchlinsky M, Sisler JR, et al. (1998) Marker rescue of the host range restriction defects of modified vaccinia virus Ankara. Virology 251: 334-342.
40. Drexler I, Heller K, Wahren B, Erfle V, Sutter G, (1998) Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 79 (Pt 2): 347-352.
41. Carroll MW, Moss B, (1997) Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238: 198-211.
42. Mayrhofer J, Coulibaly S, Hessel A, Holzer GW, Schwendinger M, et al. (2009) Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. J Virol 83: 5192-5203.
43. Holzer GW, Falkner FG, (1997) Construction of a vaccinia virus deficient in the essential DNA repair enzyme uracil DNA glycosylase by a complementing cell line. J Virol 71: 4997-5002.
44. Ober BT, Bruhl P, Schmidt M, Wieser V, Gritschenberger W, et al. (2002) Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara. J Virol 76: 7713-7723.
45. Staib C, Drexler I, Ohlmann M, Wintersperger S, Erfle V, et al. (2000) Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques 28: 1137-6 1148.
46. Holzer GW, Gritschenberger W, Mayrhofer JA, Wieser V, Dorner F, et al. (1998) Dominant host range selection of vaccinia recombinants by rescue of an essential gene. Virology 249: 160-166.
47. Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, et al. (1985) Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229: 726-733.
48. Scheiflinger F, Dorner F, Falkner FG, (1998) Transient marker stabilisation: a general procedure to construct marker-free recombinant vaccinia virus. Arch Virol 143: 467-474.
49. Wyatt LS, Earl PL, Vogt J, Eller LA, Chandran D, et al. (2008) Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines. Vaccine 26: 486-493.
50. Wyatt LS, Shors ST, Murphy BR, Moss B, (1996) Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14: 1451-1458.
51. Monath TP, (1986) The Togaviridae and Flaviviridae. In: Schleisinger S, Schleisinger MJ, editors. Pathology of the Flavivirus Plenum Press, New York pp. 375-440.
52. Hermans IF, Silk JD, Yang J, Palmowski MJ, Gileadi U, et al. (2004) The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods 285: 25-40.
53. Ramirez JC, Gherardi MM, Esteban M, (2000) Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 74: 923-933.
54. Nam JH, Wyatt LS, Chae SL, Cho HW, Park YK, et al. (1999) Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes. Vaccine 17: 261-268.
55. Tykodi SS, Thompson JA, (2008) Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. Expert Opin Biol Ther 8: 1947-1953.
56. Holzer GW, Coulibaly S, Aichinger G, Savidis-Dacho H, Mayrhofer J, et al. (2011) Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection. Vaccine 29: 4132-4141.
57. Op De BA, Molenkamp R, Caron M, Ben YA, Bredenbeek P, et al. (2003) Role of the transmembrane domains of prM and E proteins in the formation of yellow fever virus envelope. J Virol 77: 813-820.
58. Aberle JH, Aberle SW, Allison SL, Stiasny K, Ecker M, et al. (1999) A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms. J Immunol 163: 6756-6761.
59. Bejon P, Peshu N, Gilbert SC, Lowe BS, Molyneux CS, et al. (2006) Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Clin Infect Dis 42: 1102-1110.
60. Cosma A, Nagaraj R, Staib C, Diemer C, Wopfner F, et al. (2007) Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART. AIDS Res Hum Retroviruses 23: 782-793.
61. Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, et al. (2006) Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 12: 3416-3424.
62. Ramirez JC, Gherardi MM, Rodriguez D, Esteban M, (2000) Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 74: 7651-7655.
63. Cooney EL, Collier AC, Greenberg PD, Coombs RW, Zarling J, et al. (1991) Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337: 567-572.
64. Rooney JF, Wohlenberg C, Cremer KJ, Moss B, Notkins AL, (1988) Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J Virol 62: 1530-1534.
65. Perkus ME, Piccini A, Lipinskas BR, Paoletti E, (1985) Recombinant vaccinia virus: immunization against multiple pathogens. Science 229: 981-984.
66. Klinman DM, Conover J, Bloom ET, Weiss W, (1998) Immunogenicity and efficacy of a DNA vaccine in aged mice. J Gerontol A Biol Sci Med Sci 53: B281-B286.
67. Garg M, Luo W, Kaplan AM, Bondada S, (1996) Cellular basis of decreased immune responses to pneumococcal vaccines in aged mice. Infect Immun 64: 4456-4462.
68. Bender BS, Small PA Jr, (1993) Heterotypic immune mice lose protection against influenza virus infection with senescence. J Infect Dis 168: 873-880.
69. Barrett AD, Gould EA, (1986) Comparison of neurovirulence of different strains of yellow fever virus in mice. J Gen Virol 67 (Pt 4): 631-637.
70. Tesh RB, Guzman H, da Rosa AP, Vasconcelos PF, Dias LB, et al. (2001) Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J Infect Dis 183: 1431-1436.
71. Meier KC, Gardner CL, Khoretonenko MV, Klimstra WB, Ryman KD, (2009) A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog 5: e1000614.